JP2015519344A - 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション - Google Patents

炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション Download PDF

Info

Publication number
JP2015519344A
JP2015519344A JP2015514137A JP2015514137A JP2015519344A JP 2015519344 A JP2015519344 A JP 2015519344A JP 2015514137 A JP2015514137 A JP 2015514137A JP 2015514137 A JP2015514137 A JP 2015514137A JP 2015519344 A JP2015519344 A JP 2015519344A
Authority
JP
Japan
Prior art keywords
protein
pore
reagent
peptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519344A5 (cg-RX-API-DMAC7.html
Inventor
リャオ，シャオリー
ラビドー，エイミー，イー．
ペンテルテ，ブラッドリー，エル．
リン，ジンジン
アカイ，ギゼム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2015519344A publication Critical patent/JP2015519344A/ja
Publication of JP2015519344A5 publication Critical patent/JP2015519344A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015514137A 2012-05-21 2013-05-21 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション Pending JP2015519344A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261649866P 2012-05-21 2012-05-21
US201261649421P 2012-05-21 2012-05-21
US61/649,421 2012-05-21
US61/649,866 2012-05-21
PCT/US2013/042118 WO2013177231A1 (en) 2012-05-21 2013-05-21 Translocation of non-natural chemical entities through anthrax protective antigen pore

Publications (2)

Publication Number Publication Date
JP2015519344A true JP2015519344A (ja) 2015-07-09
JP2015519344A5 JP2015519344A5 (cg-RX-API-DMAC7.html) 2016-07-07

Family

ID=49624302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514137A Pending JP2015519344A (ja) 2012-05-21 2013-05-21 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション

Country Status (5)

Country Link
US (2) US9731029B2 (cg-RX-API-DMAC7.html)
EP (1) EP2852619A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015519344A (cg-RX-API-DMAC7.html)
CA (1) CA2874436A1 (cg-RX-API-DMAC7.html)
WO (2) WO2013177221A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511279A (ja) * 2013-03-15 2016-04-14 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 免疫リガンド／ペイロード複合体の生産方法
JP2018531008A (ja) * 2015-09-25 2018-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
ES2881535T3 (es) 2011-03-15 2021-11-29 Massachusetts Inst Technology Detección multiplexada con indicadores codificados con isótopos
US10415024B2 (en) 2012-11-16 2019-09-17 Poseida Therapeutics, Inc. Site-specific enzymes and methods of use
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
KR20170098821A (ko) 2014-12-17 2017-08-30 에프. 호프만-라 로슈 아게 소르타아제를 사용한 １ 단계로의 이중 폴리펩티드 컨쥬게이션을 위한 효소 원-포트 반응
WO2016096740A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Activity assay for bond forming enzymes
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
US10704035B2 (en) 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 可溶性ソルターゼａ
JP6998863B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 深共融溶媒におけるソルターゼａを利用したアミド基転移
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11519905B2 (en) 2017-04-07 2022-12-06 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
CN108504670B (zh) * 2018-02-27 2022-01-04 温州医科大学 一种大肠杆菌冷休克助溶型表达质粒的构建方法及其应用
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
EP3762404A4 (en) 2018-03-07 2022-05-11 Epicypher, Inc. ENGINEERING OF PEPTIDE LIGASE-MEDIATED RECOMBINANT NUCLEOSOMES
EP3797115A4 (en) * 2018-05-22 2022-07-06 The University Of Sydney NEW SYNTHETIC PROCESSES USING NATIVE CHEMICAL LIGATION IN FLOW
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
WO2023178327A1 (en) * 2022-03-17 2023-09-21 Ohio State Innovation Foundation Membrane translocation domains and uses thereof
JP2025515178A (ja) * 2022-05-04 2025-05-13 オハイオ・ステイト・イノベーション・ファウンデーション 植物細胞内への薬剤送達のための組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018332A2 (en) * 1993-02-12 1994-08-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and uses thereof
JP2004515238A (ja) * 2000-12-08 2004-05-27 セプテゲン リミテッド Ｇｐｃｒに関連する酵母ベースのアッセイ
WO2011133704A2 (en) * 2010-04-20 2011-10-27 Whitehead Institute For Biomedical Researh Modified polypeptides and proteins and uses thereof
WO2013126690A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
DE69837170T2 (de) 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
WO2003074554A2 (en) 2002-03-05 2003-09-12 Fundacion Galileo Apoptogenic-bacteriocins combining broad spectrum antibiotic and selective anti-tumoral activities, and compositions and uses thereof
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
WO2007100358A2 (en) 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
WO2007083175A1 (en) 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018332A2 (en) * 1993-02-12 1994-08-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and uses thereof
JP2004515238A (ja) * 2000-12-08 2004-05-27 セプテゲン リミテッド Ｇｐｃｒに関連する酵母ベースのアッセイ
WO2011133704A2 (en) * 2010-04-20 2011-10-27 Whitehead Institute For Biomedical Researh Modified polypeptides and proteins and uses thereof
WO2013126690A1 (en) * 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 66, no. 8, JPN6017007232, 2006, US, pages 4339 - 4348, ISSN: 0003511605 *
MOLECULAR MICROBIOLOGY, vol. 15, no. 4, JPN6017007228, 1995, US, pages 661 - 666, ISSN: 0003511603 *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 93, no. 16, JPN6017007230, 1996, US, pages 8437 - 8442, ISSN: 0003511604 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511279A (ja) * 2013-03-15 2016-04-14 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 免疫リガンド／ペイロード複合体の生産方法
JP2018531008A (ja) * 2015-09-25 2018-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法

Also Published As

Publication number Publication date
WO2013177231A1 (en) 2013-11-28
EP2852619A1 (en) 2015-04-01
WO2013177221A1 (en) 2013-11-28
CA2874436A1 (en) 2013-11-28
WO2013177231A8 (en) 2014-01-16
US9731029B2 (en) 2017-08-15
US20150152134A1 (en) 2015-06-04
US20150165062A1 (en) 2015-06-18
EP2852619A4 (en) 2016-04-27
US9498538B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
JP2015519344A (ja) 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション
US9303075B2 (en) Cell-penetrating peptides and uses thereof
Tsukiji et al. Sortase‐mediated ligation: a gift from gram‐positive bacteria to protein engineering
JP4907542B2 (ja) 治療、診断およびクロマトグラフィーに使用するためのタンパク質複合体
Cromm et al. Protease-resistant and cell-permeable double-stapled peptides targeting the Rab8a GTPase
KR101317100B1 (ko) 세포-침투성 펩티드로서 유용한 펩티드
JP2005529590A (ja) ＡＲＥ含有ｍＲＮＡとＨｕＲタンパク質の結合のインヒビターの同定方法
US20120283136A1 (en) Compositions and methods for the rapid biosynthesis and in vivo screening of biologically relevant peptides
WO2017070742A1 (en) Use of spycatcher as a protein scaffold for peptide display; and spycatcher/spytag cyclised peptides displayed on bacteriophage
WO2015022504A2 (en) Peptide conjugates
Brown et al. Multiple synthetic routes to the mini-protein omomyc and coiled-coil domain truncations
Deuss et al. Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo
Vickers et al. Interaction of ASOs with PC4 is highly influenced by the cellular environment and ASO chemistry
US11865181B2 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
Schissel et al. In-Cell Penetration Selection–Mass Spectrometry Produces Noncanonical Peptides for Antisense Delivery
US20170049906A1 (en) Translocation of non-natural chemical entities through anthrax protective antigen pore
CN110191953A (zh) 通过接近增强的反应性实现分裂蛋白模板组装的方法
RU2842811C1 (ru) Новые способы доставки в клетку
WO2023068328A1 (ja) 標的ペプチド分解誘導剤
KR20130103301A (ko) 전사인자에 특이적으로 결합하는 ｔｆ-ｂｐｂ
Hung Developing peptide and antibody-mimetic ligands for the cell surface receptor beta2AR and DC-SIGN
HK1180232A (en) Cell-penetrating peptides and uses thereof
HK1180232B (en) Cell-penetrating peptides and uses thereof
KR20110116930A (ko) 이온채널에 특이적으로 결합하는 이온채널―ｂｐｂ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180227